🇺🇸 FDA
Drug

sparsentan

Brand: FILSPARI

approved

Quick answer

sparsentan (FILSPARI), is a pharmaceutical active ingredient, associated with Travere Therapeutics, with approved status in the US.

Key facts

INN
sparsentan
Brand
FILSPARI
Route
ORAL
Formulation
TABLET
Originator
Travere Therapeutics

Related news

FDA Approves FILSPARI (Sparsentan) for FSGS: First Treatment for Rare Kidney Disease
NewsNephrology - Focal Segmental Glomerulosclerosis (FSGS)Apr 15, 2026

FDA Approves FILSPARI (Sparsentan) for FSGS: First Treatment for Rare Kidney Disease

Travere Therapeutics receives FDA approval for FILSPARI (sparsentan), the first approved treatment for FSGS, a rare kidney disorder leading to kidney failure.

Dr. Sarah Mitchell

Frequently asked questions

What is sparsentan?

sparsentan (FILSPARI), is a pharmaceutical active ingredient, associated with Travere Therapeutics, with approved status in the US.

What is the brand name for sparsentan?

FILSPARI is a marketed brand name for sparsentan. Check FDA Drugs@FDA for the current US label holder.